Next-Generation Sequencing Diagnostics Patent Landscape Analysis Report 2026 Edition

Next-Generation Sequencing Diagnostics Market Size, Growth Trends, and Industry Outlook

Next-generation sequencing diagnostics convert tumour, blood and germline samples into clinically actionable genomic reports. Demand comes from oncology, inherited disease, reproductive health and infectious disease laboratories that need many markers read in a single run. Targeted panels dominate routine use, and whole-genome testing is gaining ground in paediatric and critical care settings. Reimbursement coverage and in vitro diagnostic approvals decide how fast each test format reaches routine practice.

Market growth is driven by comprehensive genomic profiling in oncology, where one sequencing run replaces a series of single-gene tests. Cancer accounted for about 20 million new cases worldwide in 2022 according to GLOBOCAN, so each additional biomarker-guided therapy enlarges the tested population.

Regulatory approvals show that distributable kits now qualify as companion diagnostics. TruSight Oncology Comprehensive gained FDA approval in 2024 with NTRK and RET claims, and Medicare coverage followed, which opened reimbursed access for community oncology. The Oncomine Dx Express Test on the Genexus Dx system, approved in July 2025 with an EGFR exon 20 claim for sunvozertinib, shortens turnaround and lets hospital laboratories run tests in house. Both approvals pull sequencing volume from reference laboratories into hospitals and increase demand for panel, chemistry and software patents.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Next-Generation Sequencing Diagnostics Patent Filing Trends and Innovation Activity

Next-generation sequencing diagnostics attract patent filings from instrument makers, assay developers, liquid biopsy companies, clinical laboratories and universities. Filings concentrate on library preparation, hybrid-capture and amplicon enrichment, error-suppression chemistry, cell-free DNA methylation analysis and variant interpretation software.

The dataset contains more than 16,500 patent families, with filing activity peaking between 2021 and 2024. That peak follows the maturing of cell-free DNA assays and the first wave of FDA-approved sequencing kits with companion diagnostic claims.

Growing demand for tumour profiling, early cancer detection and inherited disease testing has translated into sustained filings on enrichment chemistry, assay design and bioinformatics.

Scope of the Next-Generation Sequencing Diagnostics Patent Landscape Analysis Report

The report covers patents on sequencing chemistry and instruments used for clinical testing, targeted gene panels, whole exome and whole genome workflows, transcriptome assays and cell-free DNA liquid biopsy methods. Sample preparation, unique molecular identifier tagging and target enrichment claims are included.

Bioinformatics claims on alignment, variant calling, copy number detection, fusion detection and clinical report generation fall inside the scope. Patents on research-only sequencing instruments are included where claims address diagnostic sample types or clinical workflows.

Assignees analysed include sequencing instrument makers, in vitro diagnostic companies, liquid biopsy developers, clinical laboratory networks, universities and research institutes holding granted patents and pending applications.

Global Next-Generation Sequencing Diagnostics Patent Landscape Analysis

Next-Generation Sequencing Diagnostics Patent Filing Trend Analysis

Annual patent filings in next-generation sequencing diagnostics grew at an estimated 8 to 10 percent per year between 2020 and 2024. Cell-free DNA assay development, tumour-informed monitoring tests and the rise of machine-learning variant callers drove this growth.

Grants in 2025 exceeded 1,900, with a rising share covering methylation-based detection, error-corrected enrichment and automated sample-to-report workflows. Publication lags of 18 months mean that 2025 and 2026 filings continue to appear in the data.

Leading Companies and Assignee Analysis in the Next-Generation Sequencing Diagnostics Patent Landscape

Geographic Analysis of Next-Generation Sequencing Diagnostics Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

The United States leads in filing volume, supported by the concentration of instrument makers, liquid biopsy developers and academic medical centres. China ranks second through BGI Genomics, MGI Tech and a growing set of domestic assay developers, and Europe ranks third with activity from Roche, Qiagen and university groups.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Next-Generation Sequencing Diagnostics Technology Segmentation and Innovation Areas

The report segments patent activity by the following technology clusters:

• Library preparation and target enrichment chemistry
• Sequencing chemistry and clinical instruments
• Variant calling and clinical bioinformatics
• Cell-free DNA liquid biopsy assays
• Comprehensive genomic profiling panels

Among these, sequencing chemistry and clinical instruments hold the largest share of patent families because of the long filing history of sequencing by synthesis and semiconductor platforms.

Competitive Landscape and Emerging Trends in the Next-Generation Sequencing Diagnostics Market

Competition combines instrument incumbents with assay-led specialists. Illumina, Thermo Fisher Scientific and BGI Genomics defend chemistry and platform claims, while Roche extends its position through Foundation Medicine panels and a new sequencing by expansion platform. Guardant Health builds around cell-free DNA enrichment and methylation claims, and its Shield test gained FDA approval in July 2024 for colorectal cancer screening.

Companies are focusing on:

• Hybrid-capture and amplicon target enrichment
• Unique molecular identifiers and error suppression
• Cell-free DNA methylation and fragmentomics
• Comprehensive genomic profiling kit design
• Automated sample-to-answer library preparation
• Variant calling and copy number inference software
• Clinical report generation and variant classification

Emerging innovation themes include multi-cancer early detection assays built on methylation signatures and tumour-informed minimal residual disease monitoring. Long-read clinical sequencing for structural variants, same-day whole-genome workflows and foundation-model approaches to variant interpretation are also gaining claims.

Strategic Insights from the Next-Generation Sequencing Diagnostics Patent Landscape

Patent activity is moving from single-gene tests toward multi-analyte sequencing kits that carry companion diagnostic claims. Platform owners protect chemistry and instrument claims, and assay developers file on enrichment, methylation and software, which creates both licensing opportunities and overlap risk in cell-free DNA workflows.

Technology segments, assignee portfolios and jurisdiction trends are analysed across the full dataset. The report provides actionable intelligence supporting:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Next-Generation Sequencing Diagnostics Patent Landscape Analysis

Patent data were collected from the USPTO, EPO, WIPO PATENTSCOPE, CNIPA, JPO and KIPO databases, with family consolidation based on priority claims. Queries combined CPC classes C12Q 1/6869, C12Q 1/6886, C12Q 1/6806 and G16B 30/00 with keyword sets for sequencing, genomic profiling and diagnostic testing.

Records were screened by title, abstract and claims to remove agricultural, forensic and pure research sequencing patents. Assignee names were normalised for subsidiaries and acquisitions, and counts were rounded to reflect search uncertainty.

The market side draws on regulatory databases such as FDA premarket approval records and EUDAMED, company filings, clinical trial registries and peer-reviewed oncology and genetics literature. These inputs confirm commercial relevance for each technology cluster.

Related Reports

Next Generation Sequencing Market

Nanopore Sequencing Market

ctDNA Technologies Patent Landscape Analysis Report